Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database

Rippel, N., Tremblay, D., Zubizarreta, N., Podoltsev, N., Gotlib, J., Heaney, M., Kuykendall, A., O’Connell, C., Shammo, J. M., Fleischman, A., Kremyanskaya, M., Hoffman, R., Mesa, R., Yacoub, A., & Mascarenhas, J. (2022). Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leukemia Research, 119, 106903. https://doi.org/10.1016/j.leukres.2022.106903
Authors:
Noa Rippel
Douglas Tremblay
Nicole Zubizarreta
Nikolai Podoltsev
Jason Gotlib
Mark Heaney
Andrew Kuykendall
Casey O'Connell
Jamile M. Shammo
Angela Fleischman
Marina Kremyanskaya
Ronald Hoffman
Ruben Mesa
Abdulraheem Yacoub
John Mascarenhas
Affiliated Authors:
Mark Heaney
Author Keywords:
anagrelide
polycythemia vera
thrombocytosis
Publication Type:
Article
Unique ID:
10.1016/j.leukres.2022.106903
PMID:
Publication Date:
Data Source:
Scopus

Record Created: